Parathyroidectomy and Mobility Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-08-15

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates whether surgical removal of the parathyroid gland (parathyroidectomy) improves physical function and mobility in older adults with primary hyperparathyroidism (PHPT). PHPT, a common endocrine disorder in older adults, is associated with reduced muscle strength, mobility, and quality of life. This prospective observational study will enroll up to 80 participants aged 60 and older undergoing parathyroidectomy at UF Health. Participants will complete physical performance tests, wear an Actigraph device to assess physical activity, and provide blood samples for biomarker analysis at pre- and post-operative time points. The goal is to characterize changes in physical function and activity following surgery and to identify biomarkers that may predict mobility improvements. Findings will help inform future larger-scale studies and could expand surgical indications for PHPT in older adults.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Proximal Humerus Fractures in the Elderly

NCT02566018

Humeral Fractures

COMPLETED

Rehabilitation Following Displaced Proximal Humerus Fractures

NCT05302089

Shoulder Fractures

COMPLETED NA

Relationship Between Mortality Rates of Fractures in Different Sites and Several Factors in Elderly Patients

NCT07147504

Fracture Lower Leg Fracture Dislocation of Upper Limb Joint Spinal Fractures

NOT_YET_RECRUITING

Preoperative Gluteal Muscle Atrophy: A Silent Predictor of THA Dislocation.

NCT06571604

Dislocation Total Hip Arthroplasty Muscle Degeneration

COMPLETED

Cross-education for Proximal Humerus Fracture Rehabilitation

NCT03017105

Proximal Humerus Fractures (to be Managed Non-operatively)

TERMINATED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperparathyroidism Parathyroid Mobility

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adults aged 60 and above with primary hyperparathyroidism

Participants who are undergoing a parathyroidectomy at UF health

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 60 years;
* Biochemical diagnosis of hypercalcemic (corrected serum calcium \>10.2 mg/dL or ionized serum calcium \>1.31 mmol/dL or 5.2 mg/dL on at least one serum sample) primary hyperparathyroidism as determined by board-certified endocrinologist or endocrine surgeon;
* Undergoing parathyroidectomy at UF Health;
* Willing and able to give informed consent.

Exclusion:

* Failure to provide informed consent;
* Biochemical diagnosis of eucalcemic primary hyperparathyroidism (corrected serum calcium ≤10.2 mg/dL or ionized serum calcium ≤1.31 mmol/dL or 5.2 mg/dL on at least one serum sample);
* Elected not to undergo parathyroidectomy at UF Health;
* Major surgery as deemed by principal investigator or hip/knee replacement in the past 6 months;
* Fractures to the hands, arms or legs within the last 6 months;
* Traumatic accident (i.e. motor vehicle collision, fall from elevation, etc.) resulting in orthopedic trauma or requiring prolonged immobilization (\>2 weeks) within the last 6 months;
* Blood transfusion within the past 3 months;
* Self-reported myocardial infarction, cerebrovascular accident, or unstable angina within the past 6 months;
* NYHA Class 3 or 4 congestive heart failure;
* Major psychiatric disorder;
* Cancer requiring treatment in the past 1 year (including metastatic cancer), except for locally treated non-melanoma skin cancers or cancers that have clearly been cured or in the opinion of the investigator carry an excellent prognosis (e.g., Stage 1 cervical cancer);
* Renal failure requiring hemodialysis or peritoneal dialysis
* Use of bone-modifying therapies (alendronate \[Fosamax\], zoledronic acid \[Reclast\], denosumab \[Prolia or Xgeva\], or romosozumab \[Evenity\]) within 1 month of planned surgery
* Planning to permanently leave the area within 3 months of parathyroidectomy;
* Vision or hearing impairment - defined as unable to read or listen/follow instructions despite the use of maximal assistive devices (i.e. contact lenses, glasses, hearing aids, etc.)
* Participating in another clinical trial or has received an investigational product within 30 days prior to screening/enrollment.

Minimum Eligible Age

60 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No